Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Diabetes Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Ther Apher Dial. 2021 Oct;25(5):586-594. doi: 10.1111/1744-9987.13618. Epub 2021 Feb 2.
FreeStyle Libre has been approved for use in patients undergoing hemodialysis (HD) in Japan, unlike Europe and the United States; however, evidence regarding its accuracy in such patients is sparse. Forty-one participants with type 2 diabetes undergoing HD were recruited. The overall mean absolute relative difference and mean absolute difference were 23.4% and 33.9 mg/dL, respectively. Sensor glucose levels and capillary glucose levels were significantly correlated (r = 0.858, P < .01), although the sensor glucose levels were significantly lower than the capillary glucose levels. The accuracy of FreeStyle Libre in patients undergoing HD became deteriorated with the days of usage. The percentage of sensor results in Zones A and B in the consensus error grid analysis and in the Clarke error grid analysis were 99.7% and 99.0%, respectively. Its insufficient accuracy necessitates adjunct usage of FreeStyle Libre with self-monitoring of blood glucose in patients undergoing HD.
利舒坦血糖仪已在日本获准用于血液透析（HD）患者，但在欧洲和美国尚未获批；然而，有关其在这类患者中准确性的数据有限。本研究纳入了 41 名接受 HD 的 2 型糖尿病患者。总体平均绝对相对差异和平均绝对差异分别为 23.4%和 33.9mg/dL。传感器血糖水平与毛细血管血糖水平显著相关（r=0.858，P<0.01），尽管传感器血糖水平显著低于毛细血管血糖水平。利舒坦血糖仪在 HD 患者中的准确性随使用天数的增加而恶化。共识误差网格分析和 Clarke 误差网格分析中传感器结果在 A 区和 B 区的百分比分别为 99.7%和 99.0%。其准确性不足，需要在 HD 患者中辅助使用利舒坦血糖仪与自我监测血糖。
